WO1994017123A1 - Sulfate of n-acetylneuraminic acid homopolymer, process for producing the same, anti-hiv drug containing said sulfate, method of treating aids with said sulfate, use of said sulfate for treating aids, and use of said sulfate for producing the drug - Google Patents
Sulfate of n-acetylneuraminic acid homopolymer, process for producing the same, anti-hiv drug containing said sulfate, method of treating aids with said sulfate, use of said sulfate for treating aids, and use of said sulfate for producing the drug Download PDFInfo
- Publication number
- WO1994017123A1 WO1994017123A1 PCT/JP1994/000111 JP9400111W WO9417123A1 WO 1994017123 A1 WO1994017123 A1 WO 1994017123A1 JP 9400111 W JP9400111 W JP 9400111W WO 9417123 A1 WO9417123 A1 WO 9417123A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sulfate
- acid
- residues
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- 229920001519 homopolymer Polymers 0.000 title claims abstract description 43
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 title claims abstract description 35
- 238000000034 method Methods 0.000 title claims abstract description 28
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 title claims abstract description 17
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 title claims abstract description 16
- 239000003814 drug Substances 0.000 title claims abstract description 13
- 229940079593 drug Drugs 0.000 title claims abstract description 9
- 230000036436 anti-hiv Effects 0.000 title abstract description 14
- 150000003839 salts Chemical class 0.000 claims abstract description 28
- 208000030507 AIDS Diseases 0.000 claims abstract description 16
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- 239000002253 acid Substances 0.000 claims description 57
- -1 sulfate ester Chemical class 0.000 claims description 36
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 claims description 18
- 229940124411 anti-hiv antiviral agent Drugs 0.000 claims description 18
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 9
- 239000000654 additive Substances 0.000 claims description 8
- 239000003054 catalyst Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 7
- 150000002148 esters Chemical class 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 230000001180 sulfating effect Effects 0.000 claims description 3
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical group CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 claims description 2
- PMDCZENCAXMSOU-UHFFFAOYSA-N N-ethylacetamide Chemical compound CCNC(C)=O PMDCZENCAXMSOU-UHFFFAOYSA-N 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- CDIDCIDDYQNFDJ-UHFFFAOYSA-N hydron;piperidin-1-ium;sulfate Chemical compound OS(O)(=O)=O.C1CCNCC1 CDIDCIDDYQNFDJ-UHFFFAOYSA-N 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 3
- 239000010452 phosphate Substances 0.000 claims 3
- SQVRNKJHWKZAKO-LUWBGTNYSA-N N-acetylneuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-LUWBGTNYSA-N 0.000 claims 2
- XDIAMRVROCPPBK-UHFFFAOYSA-N 2,2-dimethylpropan-1-amine Chemical compound CC(C)(C)CN XDIAMRVROCPPBK-UHFFFAOYSA-N 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 claims 1
- 229910006069 SO3H Inorganic materials 0.000 abstract 2
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 abstract 2
- 230000000694 effects Effects 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 11
- 241000725303 Human immunodeficiency virus Species 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 7
- 230000000144 pharmacologic effect Effects 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 230000002429 anti-coagulating effect Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000014508 negative regulation of coagulation Effects 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 229960000633 dextran sulfate Drugs 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 208000037357 HIV infectious disease Diseases 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 231100001083 no cytotoxicity Toxicity 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 2
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 2
- 229960002555 zidovudine Drugs 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- LHEJDBBHZGISGW-UHFFFAOYSA-N 5-fluoro-3-(3-oxo-1h-2-benzofuran-1-yl)-1h-pyrimidine-2,4-dione Chemical compound O=C1C(F)=CNC(=O)N1C1C2=CC=CC=C2C(=O)O1 LHEJDBBHZGISGW-UHFFFAOYSA-N 0.000 description 1
- 208000023514 Barrett esophagus Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- XTHPWXDJESJLNJ-UHFFFAOYSA-M chlorosulfate Chemical compound [O-]S(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-M 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- KRVSOGSZCMJSLX-UHFFFAOYSA-L chromic acid Substances O[Cr](O)(=O)=O KRVSOGSZCMJSLX-UHFFFAOYSA-L 0.000 description 1
- 229940055042 chromic sulfate Drugs 0.000 description 1
- GRWVQDDAKZFPFI-UHFFFAOYSA-H chromium(III) sulfate Chemical compound [Cr+3].[Cr+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRWVQDDAKZFPFI-UHFFFAOYSA-H 0.000 description 1
- 229910000356 chromium(III) sulfate Inorganic materials 0.000 description 1
- 239000011696 chromium(III) sulphate Substances 0.000 description 1
- 235000015217 chromium(III) sulphate Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 229940068998 egg yolk phospholipid Drugs 0.000 description 1
- 239000008344 egg yolk phospholipid Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- AWJWCTOOIBYHON-UHFFFAOYSA-N furo[3,4-b]pyrazine-5,7-dione Chemical compound C1=CN=C2C(=O)OC(=O)C2=N1 AWJWCTOOIBYHON-UHFFFAOYSA-N 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- YXJYBPXSEKMEEJ-UHFFFAOYSA-N phosphoric acid;sulfuric acid Chemical compound OP(O)(O)=O.OS(O)(=O)=O YXJYBPXSEKMEEJ-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- UORVCLMRJXCDCP-UHFFFAOYSA-N propynoic acid Chemical compound OC(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-N 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 238000001226 reprecipitation Methods 0.000 description 1
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 1
- 229960001755 resorcinol Drugs 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/321—Polymers modified by chemical after-treatment with inorganic compounds
- C08G65/326—Polymers modified by chemical after-treatment with inorganic compounds containing sulfur
Definitions
- N-acetylneuraminic acid homopolymer sulfate a method for producing the same, an anti-HIV agent containing the sulfate, a method for treating AIDS using the sulfate, a use of the sulfate for the treatment of AIDS, Use of said sulphate to produce a medicament
- the present invention relates to a sulfate ester of N-acetylnoylamino acid homopolymer, a method for producing the same, and a drug having an effect on human immunodeficiency virus (HIV) containing the sulfate ester as an active ingredient.
- HIV human immunodeficiency virus
- An anti-HIV agent a method for treating AIDS using the sulfate, the use of the ester for the treatment of AIDS, and the use of the ester for producing the medicament.
- AIDS Acquired immunodeficiency syndrome
- HIV HIV
- the search for HIV drugs is an urgent task.
- Known anti-HIV agents to date include reverse transcriptase inhibitors such as azidothymidine and HIV targets Sulfated polysaccharides such as heparin that suppress cell infection can be mentioned (for example, Japanese Patent Application Laid-Open Nos. Sho 62-215559, Japanese Patent Publication No. Hei 2-7577, and Japanese Patent Laid-Open No. See Japanese Patent Application Publication No. 91207).
- reverse transcriptase inhibitors such as azidothymidine, which suppress the growth of H-factory V, have strong side effects on the living body because they act on the nucleic acid synthesis system, making long-term administration difficult.
- sulfated polysaccharides such as heparin have been used as anticoagulants by nature, and have a relatively strong anticoagulant effect compared to anti-HIV activity, and have anti-HIV activity. At a concentration that expresses, the anticoagulant effect is also very strong. This side effect (anticoagulant effect) makes it difficult to develop an anti-HIV agent.
- An object of the present invention is to provide a drug having an excellent anti-HIV action and no side effects.
- the present inventors have conducted intensive studies in view of the above problems, and as a result, have found that a novel ester form of a novel N-acetylneuraminic acid homopolymer has a side effect such as an anticoagulant effect at a dose that exhibits an anti-HIV effect. Was found to be very weak.
- R represents a hydrogen atom or a S 0 3 H same or different
- n is an integer of 5-1 0 0 0.
- the number of S 0 3 H residues per molecule N- Asechiruno Lee run-acid residue is from 0.1 to 3.
- the present invention also provides a sulfate ester of an N-acetyl neuraminic acid homopolymer represented by the formula: and a pharmaceutically acceptable salt thereof.
- the present invention relates to a method for preparing a catalyst comprising 0.5 to 200 parts by weight of a catalyst and 0.2 to 30 parts by weight of 1 part by weight of an N-acetyl neuraminic acid homopolymer in the presence or absence of a solvent.
- General formula (I) characterized by reacting with parts by weight
- N - Asechi Renault number of S 0 3 H residues Lee La Mi emission acid residue per molecule is 0 1-3.. ]
- the present invention provides a method for treating AIDS, which comprises administering to a patient a sulfate of N-acetylnoylamic acid homopolymer or a pharmaceutically acceptable salt thereof represented by the formula:
- the present invention relates to a compound of the general formula (I) for use as a medicament:
- the present invention provides a sulfate ester of N-acetylneuraminic acid homopolymer represented by the formula or a pharmaceutically acceptable salt thereof.
- the present invention provides a compound of the general formula (I) for producing a drug for treating AIDS.
- the present invention relates to the use of a sulfuric acid ester of a homopolymer of N-acetylethylamino acid represented by the formula or a pharmaceutically acceptable salt thereof.
- n represents 5 to: an integer of L0000, preferably an integer of 6 to 200, and more preferably an integer of 6 to 70.
- the sulfate of the homopolymer of N-acetylethylamic acid of the present invention may be a single compound in which n is only one kind, and n may be in the range of 5 to 1000. It may be a mixture of a plurality of sulfates of N-acetylnoylamino acid homopolymer having different values.
- novel sulfate of the present invention can be produced according to the following method.
- a catalyst 0.5 to 200 parts by weight of a catalyst and 0.2 to 30 parts by weight of a sulfating agent in the presence or absence of a solvent with respect to 1 part by weight of a homopolymer of N-acetylethylamine. Is reacted.
- the reaction time is about 0.2 to 100 hours, and the reaction temperature is 0 to 90. It is about C.
- catalysts include pyridine
- the sulfating agent include chlorosulfonic acid, piperidine sulfate, salt trioxide, trimethylammine, and sulfur tritamine. Oxides and pyridines. When using an excess amount of pyridine or the like as a catalyst, it is not necessary to use a solvent.
- N-acetylnoylamic acid homopolymer is not particularly limited, but may be a homopolymer having a certain number of polymerization degrees (n). Mixtures of naturally occurring acetylenic acid homopolymers such as chromic acid may be used.
- the pharmaceutically acceptable salts include alkali metal salts such as sodium, potassium, and lithium, and alkaline earth metal salts such as magnesium and calcium. These salts can be produced by neutralizing the sulfated reaction solution with a salt such as sodium hydroxide or carbonated carbonate. After being obtained as an acid, it may be used in the form of a salt according to a conventional method.
- the sulfate ester of N-acetyl neuraminic acid homopolymer of the general formula (I) of the present invention is used as an anti-HIV agent together with various pharmacologically acceptable additives. be able to.
- the pharmaceutical composition is not particularly limited, but may be used in various forms such as oral preparations such as injections, tablets, capsules, granules, fine granules and emulsions, injections and suppositories. Can be
- the additives include a pH adjuster, a buffer, Examples thereof include a stabilizer, an isotonic agent, and a local anesthetic. By mixing these in an appropriate amount, a preparation for injection can be prepared.
- the formulation is administered intravenously, intramuscularly, subcutaneously or intraperitoneally.
- Additives when the anti-HIV agent of the present invention is prepared as an oral preparation include excipients, disintegrants, lubricants, binders, flavoring agents, flavoring agents, and the like.
- Additives when the anti-HIV agent of the present invention is prepared as a suppository include a base, a surfactant and the like.
- the above-mentioned additives include all additives usually used when preparing each preparation, and appropriate amounts of these are used.
- the amount of the ester sulfate of the N-acetylnoylamino acid homopolymer of the present invention depends on the age, sex, weight, symptoms, etc. of the patient to be administered. In general, about 1 to 10 Omg for oral preparations, about 0.1 to 20 mg for injections, about 1 to 20 mg for injections, and 1 to 50 mg for suppositories. It is preferable that the daily dose be about 1 to 100 mg, preferably 10 to 200 mg, depending on the dosage form. It is about.
- the anti-HIV agent of the present invention can be 1 By applying it to the genital area, vagina, or to the penis of men, it can also be used to prevent HIV infection.
- the novel sulfate of the N-acetyl neuraminic acid homopolymer of the present invention has an anti-HIV activity comparable to that of a conventional sulfated polysaccharide, and has a problem of anticoagulant activity. It has no side effects and low cytotoxicity, so it is useful for treating and preventing HIV. It can also be used for long-term administration.
- the measurement was performed by the KBr method using a Shimadzu infrared spectrophotometer IR-400.
- Dialysis was performed for 3 days under running water using a VISKASE SALES CORP., Pore diameter: 24 oz. 40 using a rotary evaporator. Up to approx. 10 m 1 below C After concentration under reduced pressure, the mixture was freeze-dried to obtain about 900 mg of the desired product as a powder.
- Example 2 The content of the sulfate group in the obtained sulfate was measured by the Dodgeson method, and as a result, the content was 30% by weight.
- Example 2 The content of the sulfate group in the obtained sulfate was measured by the Dodgeson method, and as a result, the content was 30% by weight.
- Example 2 The same procedure as in Example 1 was carried out except that the reaction time and the reaction temperature after the addition of colominic acid were set to 55 ° C for 2 hours, and the target sulfate was converted to a powder of about 85 O mg was obtained.
- the percentage (%) of virus-infected cells is shown in Table 1 below.
- anti-HIV activity was measured for colominic acid as a raw material instead of colominic sulfate under the same conditions. The results are shown in Table 2.
- the anti-HIV agent of the present invention can significantly suppress HIV infection at a concentration of 0.2 ⁇ g / ml, and that non-sulfated collagen It is clear that the acid has no anti-HIV activity.
- the cytotoxicity of colominic acid sulfate was tested according to Pharmacological Test Example 1 described above. That is, in the presence of 1 X 1 0 5 cells Zm l the MT one 4 cells prepared in various concentrations roller Mi phosphate sulfate, after 4 days of culture, and mosquito window down bets that number of cells. The cell viability at each final concentration when the cell viability of the control having the final concentration of colominic acid sulfate of 0 was 100% was calculated, and the cytotoxicity was evaluated.
- — indicates no cytotoxicity or anti-HIV activity.
- Active ingredient in one vial of Bratellincel LS Nitrile egg yolk phospholipid 0.6 mg
- Control (distilled water) 45 At a concentration higher than the concentration showing anti-HIV activity (50 g / m 1), the chromic sulfate of the present application did not show anti-coagulant activity. In contrast, dextran sulfate exhibited high anticoagulant activity.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU70052/94A AU670697B2 (en) | 1993-01-29 | 1994-01-27 | Sulfate of N-acetylneuraminic acid homopolymer, process for producing the same, anti-HIV drug containing said sulfate, method of treating AIDS with said sulfate, use of said sulfate for treating AIDS, and use of said sulfate for producing the drug |
US08/313,227 US5637690A (en) | 1993-01-29 | 1994-01-27 | Sulfate of n-acetylneuraminic acid homopolymer and processes for making and using the same |
EP94905216A EP0634436B1 (en) | 1993-01-29 | 1994-01-27 | Sulfate of n-acetylneuraminic acid homopolymer, process for producing the same, anti-hiv drug containing said sulfate, method of treating aids with said sulfate, use of said sulfate for treating aids, and use of said sulfate for producing the drug |
DE69414196T DE69414196T2 (de) | 1993-01-29 | 1994-01-27 | Sulfat eines n-acetyleneuraminicsaurehomopolymers, verfahren zur herstellung, anti-hiv-droge enthaltend dieses sulfat, verfahren zur behandlung von aids mit diesem sulfat, verwendung dieses sulfats in der behandlung von aids und in der herstellung von medikamenten |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP5/14117 | 1993-01-29 | ||
JP1411793 | 1993-01-29 | ||
JP5/101290 | 1993-04-27 | ||
JP5101290A JP3062906B2 (ja) | 1993-01-29 | 1993-04-27 | N−アセチルノイラミン酸ホモポリマーの硫酸エステル |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994017123A1 true WO1994017123A1 (en) | 1994-08-04 |
Family
ID=26350020
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1994/000111 WO1994017123A1 (en) | 1993-01-29 | 1994-01-27 | Sulfate of n-acetylneuraminic acid homopolymer, process for producing the same, anti-hiv drug containing said sulfate, method of treating aids with said sulfate, use of said sulfate for treating aids, and use of said sulfate for producing the drug |
Country Status (6)
Country | Link |
---|---|
US (1) | US5637690A (ja) |
EP (1) | EP0634436B1 (ja) |
JP (1) | JP3062906B2 (ja) |
AU (1) | AU670697B2 (ja) |
DE (1) | DE69414196T2 (ja) |
WO (1) | WO1994017123A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6337390B1 (en) * | 1996-05-16 | 2002-01-08 | Nissan Food Products Co., Ltd. | Compounds comprising sulfated nonulonic acid having antiviral activity |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04275295A (ja) * | 1991-03-04 | 1992-09-30 | Rikagaku Kenkyusho | オリゴシアリル−1,2−ジアルキル−Sn−グリセロール及びその合成中間体 |
JPH04279526A (ja) * | 1991-03-07 | 1992-10-05 | Mect Corp | 腎疾患治療薬 |
JPH05214003A (ja) * | 1992-02-04 | 1993-08-24 | Mect Corp | 好中球遊走阻止薬 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0285357A3 (en) * | 1987-03-31 | 1989-10-25 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Control of retroviruses |
JP3083858B2 (ja) * | 1991-01-21 | 2000-09-04 | 帝國製薬株式会社 | 酸性ヘテロ多糖類、硫酸化多糖類、およびその製法 |
CA2061370A1 (en) * | 1991-03-13 | 1992-09-14 | Markus Hosang | Pharmaceutical preparations |
-
1993
- 1993-04-27 JP JP5101290A patent/JP3062906B2/ja not_active Expired - Fee Related
-
1994
- 1994-01-27 US US08/313,227 patent/US5637690A/en not_active Expired - Lifetime
- 1994-01-27 WO PCT/JP1994/000111 patent/WO1994017123A1/ja active IP Right Grant
- 1994-01-27 EP EP94905216A patent/EP0634436B1/en not_active Expired - Lifetime
- 1994-01-27 AU AU70052/94A patent/AU670697B2/en not_active Ceased
- 1994-01-27 DE DE69414196T patent/DE69414196T2/de not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04275295A (ja) * | 1991-03-04 | 1992-09-30 | Rikagaku Kenkyusho | オリゴシアリル−1,2−ジアルキル−Sn−グリセロール及びその合成中間体 |
JPH04279526A (ja) * | 1991-03-07 | 1992-10-05 | Mect Corp | 腎疾患治療薬 |
JPH05214003A (ja) * | 1992-02-04 | 1993-08-24 | Mect Corp | 好中球遊走阻止薬 |
Non-Patent Citations (1)
Title |
---|
See also references of EP0634436A4 * |
Also Published As
Publication number | Publication date |
---|---|
AU7005294A (en) | 1994-08-15 |
JP3062906B2 (ja) | 2000-07-12 |
US5637690A (en) | 1997-06-10 |
DE69414196T2 (de) | 1999-06-24 |
EP0634436A4 (en) | 1996-07-24 |
EP0634436B1 (en) | 1998-10-28 |
EP0634436A1 (en) | 1995-01-18 |
DE69414196D1 (de) | 1998-12-03 |
AU670697B2 (en) | 1996-07-25 |
JPH06279503A (ja) | 1994-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5296471A (en) | Method for controlling o-desulfation of heparin and compositions produced thereby | |
JPH0629282B2 (ja) | 解重合及び超硫酸化ヘパリン、その製造方法並びに製薬組成物 | |
EP0577756A1 (en) | New non-anticoagulant heparin derivatives | |
HU188657B (en) | Process for the preparation of anticoagulant mycopolysaccharides | |
JP2001527583A (ja) | ヘパリンのo−脱硫酸化の制御方法およびそれによって得られる組成物 | |
CA2189038A1 (en) | O-desulfated heparin derivatives, methods of making and uses thereof | |
JP2018513217A (ja) | アンチトロンビン−ヘパリンの組成物および方法 | |
JP2003512807A (ja) | デルマタン二硫酸、トロンビン生成および補体活性化阻害剤 | |
Spadarella et al. | From unfractionated heparin to pentasaccharide: Paradigm of rigorous science growing in the understanding of the in vivo thrombin generation | |
KR20020093845A (ko) | 글루탐산 n-유도체의 다당류 에스테르 | |
KR0143084B1 (ko) | 항-hiv 작용을 가진 헤파린단편 및 분획 | |
JP4051099B2 (ja) | 低分子化ヘパリン、その製造法及び医薬組成物 | |
JP2001081103A (ja) | ヒアルロン酸結合薬剤 | |
RU2183638C2 (ru) | Углеводные производные, фармацевтическая композиция на их основе | |
WO1994017123A1 (en) | Sulfate of n-acetylneuraminic acid homopolymer, process for producing the same, anti-hiv drug containing said sulfate, method of treating aids with said sulfate, use of said sulfate for treating aids, and use of said sulfate for producing the drug | |
EP0338092A1 (en) | Anti-hiv agent | |
JP2010518251A (ja) | ビオチンまたはビオチン誘導体との少なくとも1つの共有結合を含むヘパリン、これらの調製方法およびこれらの使用 | |
NZ537217A (en) | LMW-N-sulphates useful as intermediates in the preparation of LMW-K5-N, O oversulfates with antiviral and/or antiangiogenic activity and devoid of anticoagulant activity | |
JPS6354282B2 (ja) | ||
JPH0539224A (ja) | 抗炎症活性を有するコンドロイチン硫酸 コンプレツク ス,その製造方法およびそれを含有する医薬組成物 | |
US20030092671A1 (en) | Antithrombotic composition | |
JP2550452B2 (ja) | グリコサミノグリカンとアミノ酸エステルとの塩、その製造法およびそれを含有する経口投与用薬学的製剤 | |
JPS6354283B2 (ja) | ||
WO1994008595A1 (en) | Use of non-anticoagulant heparin for treating ischemia/reperfusion injury | |
RU2176915C2 (ru) | Полусинтетические сульфаминогепаросансульфаты, имеющие высокую антиметастатическую активность и пониженный геморрагический риск |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1994905216 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 08313227 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1994905216 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1994905216 Country of ref document: EP |